Form 10-Q · Quarterly report
Thermo Fisher Scientific 10-Q, filed Jul 31, 2026
- Filed
- CIK
- 0000097745
- Accession no.
- 0000097745-26-000144
Summary
Thermo Fisher Scientific reported second-quarter 2026 revenue of $11.99 billion, up 10% from a year earlier with 5% organic growth, and adjusted earnings per share of $6.03, saying customer activity continued to strengthen across its end markets. The company also completed the March 2026 acquisition of clinical-trial endpoint data provider Clario Holdings within its Laboratory Products and Biopharma Services segment.
Key points
- Second-quarter revenue rose 10% to $11.99 billion, with GAAP operating income of $2.09 billion (17.4% margin) and GAAP diluted EPS of $4.68 versus $4.28 a year earlier.
- Six-month revenue rose 8% to $23.0 billion, with 3% organic growth and adjusted EPS of $11.47 versus $10.51.
- Thermo Fisher acquired U.S.-based Clario Holdings, a provider of endpoint data solutions for clinical trials, on March 24, 2026, expanding its Laboratory Products and Biopharma Services segment.
- On September 1, 2025, Thermo Fisher acquired Solventum Corporation's filtration and separation business, adding purification and filtration technologies to its Life Sciences Solutions segment.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 11): Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.